Home >> Chemicals Listing >> hot product list by B  

Bleomycin (11056-06-7)

Identification
Name:Bleomycin
Synonyms:Bleo;Bleocin;NSC 125066;
CAS:11056-06-7
EINECS: 232-925-2
Molecular Formula: C55H84N17O21S3
Molecular Weight: 1415.55
InChI: InChI=1/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
Molecular Structure: (C55H84N17O21S3) Bleo;Bleocin;NSC 125066;
Properties
Flash Point: °C
Boiling Point: °Cat760mmHg
Density:g/cm3
Stability:No data.
Water Solubility:Soluble
Solubility:Soluble
Appearance:colourless or light yellow powder
Specification:

The IUPAC name of Bleomycin is 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium. With the CAS registry number 11056-06-7, it is also named as Bleomycinum. The classification codes are Antibiotics, antineoplastic; Antineoplastic Agents; Drug / Therapeutic Agent; Human Data; Mutation data; Reproductive Effect; Skin / Eye Irritant; Tumor data. It is colourless or light yellow powder which is a glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. And it is nonflammable. When heated to decomposition Bleomycin emits toxic fumes of NOx.

The other characteristics of this product can be summarized as: (1)#H bond acceptors: 38; (2)#H bond donors: 25; (3)#Freely Rotating Bonds: 45; (4)Polar Surface Area: 418.05 ?2; (5)Rotatable Bond Count: 36; (6)Tautomer Count: 1000; (7)Exact Mass: 1414.51898; (8)MonoIsotopic Mass: 1414.51898; (9)Topological Polar Surface Area: 685; (10)Heavy Atom Count: 96; (11)Formal Charge: 1; (12)Complexity: 2580; (13)Defined Atom StereoCenter Count: 18; (14)Undefined Atom StereoCenter Count: 1; (15)Covalently-Bonded Unit Count: 1.

Uses of Bleomycin: It is used as an anti-cancer agent, and its chemotherapeutical forms are primarily Bleomycin A2 (shown in the image) and B2. Bleomycin A2 is used as a component of the ABVD regimen in the treatment of Hodgkin lymphoma, squamous cell carcinomas, and testicular cancer, as well as in the treatment of pleurodesis and plantar warts. But this drug has many side effects. The most serious complication of bleomycin is pulmonary fibrosis and impaired lung function

When you are using this chemical, please be cautious about it as the following:
It has limited evidence of a carcinogenic effect. And it may cause heritable genetic damage. If you want to contact this product, you must wear suitable protective clothing and gloves. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 

People can use the following data to convert to the molecule structure.
1. SMILES:O=C(N)[C@@H](N)CN[C@H](c1nc(N)c(c(n1)C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@@H](C(=O)N[C@H](C(=O)NCCc2nc(cs2)c3nc(C(=O)NCCC[S+](C)C)cs3)[C@H](O)C)C)C(O[C@@H]5O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]5O[C@H]4O [C@H](CO)[C@@H](O)[C@H](OC(=O)N)[C@@H]4O)c6cncn6)C)CC(=O)N
2. InChI:InChI=1/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41,42-,43-,53+,54-/m0/s1

The following are the toxicity data which has been tested.

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD oral > 100mg/kg (100mg/kg)   Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
human LDLo intramuscular 418mg/kg (418mg/kg) LUNGS, THORAX, OR RESPIRATION: FIBROSING ALVEOLITIS

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
 
human LDLo intravenous 351mg/kg (351mg/kg) LUNGS, THORAX, OR RESPIRATION: FIBROSING ALVEOLITIS

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
 
mouse LD50 intramuscular 270mg/kg (270mg/kg)   Pharmaceutical Chemistry Journal Vol. 17, Pg. 785, 1983.
mouse LD50 intraperitoneal 35mg/kg (35mg/kg)   Journal of Antibiotics. Vol. 37, Pg. 239, 1984.
mouse LD50 intravenous 53mg/kg (53mg/kg)   Journal of Antibiotics. Vol. 31, Pg. 667, 1978.
mouse LD50 oral > 2gm/kg (2000mg/kg)   Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
mouse LD50 subcutaneous 188mg/kg (188mg/kg)   Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974.
mouse LDLo intratracheal 14mg/kg (14mg/kg)   Toxicology Letters. Vol. 30, Pg. 63, 1986.
rat LD oral > 200mg/kg (200mg/kg)   Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
rat LD50 intraperitoneal 168mg/kg (168mg/kg)   "Bleomycin: Current Status and New Development, Papers Presented in a Symposium, Oakland, CA, 1977," Carter, S.K., et al., eds., New York, Academic Press, Inc., 1978Vol. -, Pg. 311, 1978.
rat LD50 subcutaneous 168mg/kg (168mg/kg)   Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974.
rat LDLo intratracheal 4units/kg (4units/kg) LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI

LUNGS, THORAX, OR RESPIRATION: FIBROSIS (INTERSTITIAL)

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA
Lung. Vol. 161, Pg. 287, 1983.
 

Report:

IARC Cancer Review: Group 2B IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 7 (1987),p. 134.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 26 (1981),p. 97.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.

Flash Point: °C
Storage Temperature: 2-8°C
Color: white
Usage:Inhibits dna metabolism and is used as an antineoplastic, especially for solid tumors.
Safety Data
Hazard Symbols T: Toxic